【摘要】 目的观察丹参注射液治疗支气管哮喘(哮喘)患者的疗效及对CD4+CD25+Treg调节性T细胞(CD4+CD25+)的影响,探讨丹参注射液治疗哮喘的新机制。方法 62名哮喘患者随机分成对照组和丹参治疗组,记录试验前、后患者的临床症状评分、FEV1、PEF,流式细胞仪检测患者外周血单个核细胞(PBMCs)中CD4+CD25+Treg的比例。结果两组患者临床症状评分均较治疗前显著减少,治疗组的减少更为明显,且与对照组相比,差异具有显著性(P<0.05);两组患者FEV1、PEF、CD4+CD25+Treg的比例均较治疗前显著增加,治疗组的增加更为明显,且与对照组相比,差异具有显著性(P<0.05)。结论丹参注射液可有效治疗哮喘,其机制可能与促进CD4+CD25+Treg的产生有关。更多还原

【Abstract】 Objective To investigate the influences of Salvia Miltiorrhiza Injection on clinical efficacy and CD4+ CD25+ Regulatory T Cells of asthmatic patients,and elucidate the possible mechanism of salvia miltiorrhiza injection in treatment of asthma.Methods 62 asthmatic patients were randomly divided into control group and salvia miltiorrhiza-treated group.The symptom scores,forced expiratory volume in one second(FEV1)and peak flow rate(PEF)were monitored.Flow cytometry was used to detect the CD4+ CD25+ Treg ratio in PBMCs.Results Compared with before treatment,symptom scores of two groups significantly decreased(P<0.05).The decrease in therapy group was more significant than that in control group(P<0.05).Compared with before treatment,FEV1,PEF and CD4+ CD25+ Treg ratio of two groups significantly increased(P<0.05).The increase in therapy group was more significant than that in control group(P<0.05).Conclision Salvia miltiorrhiza injection could treat asthmatic patients effectively,probably by increasing the number of CD4+ CD25+ Treg.更多还原